Neuland Laboratories reported a consolidated net profit of ₹1,476.73 lakh for the quarter ended June 30, 2026, marking a 960% year-on-year increase from ₹139.00 lakh in Q1FY25. This substantial turnaround was driven by an 119% surge in revenue from operations, which reached ₹6,415.77 lakh compared to ₹2,927.53 lakh in the corresponding period of the previous fiscal year. The robust top-line expansion, coupled with effective cost management, resulted in a profit before tax of ₹1,978.47 lakh, up significantly from ₹175.70 lakh a year ago.

The Board of Directors approved the unaudited financial results at a meeting held on August 5, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the Statutory Auditors, MSK A & Associates LLP. The consolidated figures include results from wholly owned subsidiaries Neuland Laboratories Inc., USA, and Neuland Laboratories K.K., Japan. Management noted that the interim financial information of these subsidiaries, reflecting total revenue of ₹606.54 lakh and net profit after tax of ₹31.12 lakh, was not material to the Group.

Financial Performance Breakdown

Revenue growth was broad-based across geographies. Europe contributed ₹3,034.58 lakh, up significantly from ₹944.12 lakh in Q1FY25. Revenue from the USA and North America rose to ₹1,996.74 lakh from ₹657.84 lakh, while India operations generated ₹832.64 lakh. The Rest of the World segment contributed ₹551.82 lakh. Earnings per share stood at ₹115.10, a substantial increase from ₹10.83 in the previous year's quarter.

Strategic Expansion and Capacity Plans

In a strategic move to expand its sterile API capabilities, Neuland Laboratories announced a long-term Contract Development and Manufacturing Organization (CDMO) partnership with Gland Pharma Limited. Under this collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite at its JNPC facility in Visakhapatnam to support Neuland’s growing demand for sterile APIs used in microparticle depot products. The new facility, designed to add approximately 1,400 kg of annual capacity, will be constructed and operated to cGMP, USFDA, and EU standards. To secure the obligations under the associated Loan Licence Agreement, Neuland executed an irrevocable corporate guarantee of ₹40 crores in favour of Gland Pharma Limited. The promoter group has no interest in this transaction, which was executed at arm's length.

To cater to growing customer demand, the Board also approved an enhancement of manufacturing capacity at Unit 1 located in Sangareddy District, Telangana. The existing capacity of 376.5 KL, currently utilized at 91%, will be increased by 18 KL. The expansion is expected to be completed within 6–7 months and requires an investment of ₹39.8 crores (including GST), which will be financed through internal accruals. This capital expenditure aims to maintain supply resilience and meet increasing order inflows without impacting the company’s current liquidity position.

Neuland Laboratories has reported a sharp improvement in its quarterly financial performance, with consolidated net profit surging to 1.48B rupees compared to 139M rupees in the corresponding period of the previous year. The company also announced a significant capacity expansion plan at its Unit-1 facility in Bonthapally Village, backed by an investment of 398 crores.

Strong Revenue and Profitability Growth

The company's revenue for the quarter rose to 6.42B rupees from 2.93B rupees year-on-year, reflecting substantial top-line growth. EBITDA climbed to 2.23B rupees from 345M rupees in the same period last year, underscoring a marked improvement in operating performance. The EBITDA margin expanded considerably to 34.74% from 11.78% year-on-year, indicating improved operational efficiency and cost management.

The following table summarizes the key financial metrics for the quarter:

Capacity Expansion at Bonthapally Unit-1

Alongside its quarterly results, Neuland Laboratories announced plans to increase production capacity at its Unit-1 facility located in Bonthapally Village. The expansion is planned with an investment of 398 crores, signaling the company's commitment to scaling its manufacturing infrastructure.

Key Highlights

• Consolidated net profit rose to 1.48B rupees from 139M rupees year-on-year
• Revenue increased to 6.42B rupees from 2.93B rupees year-on-year
• EBITDA grew to 2.23B rupees from 345M rupees year-on-year
• EBITDA margin expanded to 34.74% from 11.78% year-on-year
• Capacity expansion planned at Unit-1, Bonthapally Village with an investment of 398 crores

The combination of strong quarterly financial results and a major capacity investment reflects a significant period of growth and operational development for Neuland Laboratories.